Amgen (AMGN)
Health Care · biotechnology · NASDAQ
Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease.
What Amgen does
Amgen is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics for serious illnesses. Its diverse portfolio includes treatments for inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology. The company is also active in the development of biosimilars and innovative small molecule and biologic therapies.
Themes: oncology, inflammation / immunology, cardiovascular health, bone health / osteoporosis, biosimilars, drug pricing / policy reform, Medicare / Medicaid reimbursement
Fundamentals
- Price$407.44 as of 2026-10-08 close
- Market cap$220.3B as of 2026-07-30 (share count; price 2026-10-08)
- 1-year return+38.3% 2025-10-08 close $294.62 → 2026-10-08 close $407.44
- P/E25.30 as of 2026-10-08
- Net margin+21.0% FY2025, SEC XBRL
- ROE+89.1% FY2025, SEC XBRL
- Debt / equity4.90 as of 2026-09-03
- Revenue growth (YoY)+9.1% as of 2026-09-03
- Revenue CAGR (3y)+11.8% SEC XBRL
- Beta0.42 as of 2026-09-03
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +2.6%; at least 15 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How AMGN compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldtop 25% 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
AMGN is not currently in any published Top 10 list. Its scores are below.
Top 10 score
63.9 #126 of 1,379 scored · #14 of 151 in Health Care
Profitability 90th (return on equity 89.1%, operating margin 24.7%) and trend 81st (a trend forming but not yet strong (ADX below 25)); weakest is valuation (33rd, price to book 18.8, price to earnings 25.3).
Left this list on 1 Oct 2026
- Left 1 Oct 2026: score 64.0, rank 16 (not compared with 1 Sep 2026 — those rows were scored under method version 3, this pass under 4, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
- Entered 18 Aug 2026: first selection for this list at rank 3, score 62.9.
- Held its place at 1 rebalance on 1 Sep 2026.
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, AMGN's dividend was covered by reported results (earnings payout 66%, free-cash-flow payout 63%). This describes past coverage, not a forecast.
- Earnings payout66% dividends / net income
- Free-cash-flow payout63% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Amgen looks technically
Amgen (AMGN) is trading 11.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 223 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 18 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 11.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +11.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $411.34 | $411.34 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $365.88 | $365.88 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 426.59. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 223 trading days ago — a "golden cross", a bullish long-term signal | 223 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 21.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) | 50.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($381.90 to $426.59) — its "stochastic" reading is 57 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 57.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $447.01 | $447.01 |
|---|---|---|
| From the 52-week high | it is 8.9% below its 52-week high (its highest price of the past year) | -8.8% |
| Above the 52-week low | it is 41.5% above its 52-week low (its lowest price of the past year) | +41.5% |
| Below the 52-week high | it is 8.9% below its highest point of the past year | 8.8% |
| Since a 20-day breakout | it made a new 20-day low about 18 trading days ago | 18 sessions |
| Since a 55-day breakout | it made a new 55-day high about 25 trading days ago | 25 sessions |
| All-time high | its highest closing price on record is $447.01 (set on 2026-08-25) | $447.01 |
| Given back of the 52-week move | over the past year its closes ranged ($290.13 to $444.12), and it has given back roughly a quarter of its rise from last year’s low — 24% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $344.03 to $348.95. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 23.8% |
| From the all-time high | it is 8.9% below its all-time high | -8.8% |
| Nearest price level | it is trading 7.6% above a support level at $376.62 — a price it turned at three times since 2026-03-11, most recently on 2026-09-16. Since 2024-10-08 it has 10 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -7.6% |
| All-time low | its lowest closing price on record is $11.22 (set on 1997-10-23) | $11.22 |
| Above the all-time low | it is 3531.8% above its all-time low | +3,532% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 70th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $10.47 between its high and its low — about 2.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $10.47 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $369.60 and $431.01 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $369.60 – $400.31 – $431.01 |
| Typical daily range (% of price) | its price moves about 2.6% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.6% |
| Stretch from the 200-day average | it is trading 4.0 daily ranges above its 200-day average price (11.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.80× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.4% since the prior reading | +0.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.7% |
|---|---|---|
| Open gap | it gapped 3.1% above the previous close 12 sessions ago and has not traded back through the level it left behind at 393.16 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.1% |
| Gap filled | a 2.0% gap down opened on 2026-07-30 has been "filled" 49 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 49 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 2.6 percentage points (the stock gained 3.6% while the market gained 1.0%) | +2.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 6.9 percentage points (the stock gained 10.7% while the market gained 3.8%) | +6.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 1.5 percentage points (the stock gained 18.9% while the market gained 17.5%) | +1.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 23.3 percentage points (the stock gained 38.3% while the market gained 15.0%) | +23.3% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 8.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 11% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $367.77 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +10.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-04 (its 8-K), so the typical buyer over that stretch is under water. That average is $409.61 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -0.5% |
Price levels it has turned at before
AMGN last closed at $407.44 on 2026-10-08. Since 2024-10-08 it has turned at 10 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $376.62 | Support | 7.6% below the last close | turned there three times · 2026-03-11 to 2026-09-16 |
| $446.42 | Resistance | 9.6% above the last close | turned there twice · 2026-08-25 to 2026-09-03 |
| $357.23 | Support | 12.3% below the last close | turned there six times · 2026-01-27 to 2026-07-15 |
| $344.80 | Support | 15.4% below the last close | turned there five times · 2025-11-13 to 2026-05-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $426.59.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 2 trading days, since 2026-10-07.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.65 mean, 1=Strong Buy…5=Strong Sell) — 29 analysts
- Mean price target$390.94 range $225.00 – $500.00; median $400.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AMGN
- Consensus EPS estimate$5.78 next reporting period, as of 2026-10-04
- Estimate change, 30 days$0.00 (0.0%) from $5.78, on 2026-08-31, 34-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Government price setting and legislative changes to reimbursement (e.g., IRA, OB3) significantly impact pricing, sales, and profitability.","High dependence on competitive intellectual property rights and the timing of market entry of generic or biosimilar competition.","Complex and evolving U.S. government price reporting regulations carry risks of substantial fines, penalties, and required retroactive rebate payments."]
What changed in the latest 10-Q
AI-assisted comparison of AMGN's 10-Q filed 2026-08-05 against the prior one filed 2026-05-01.
Management's Discussion & Analysis (MD&A)
- Added:
- In the 2026-08-05 filing, critical accounting policies and estimates are stated to have no material changes during the six months ended June 30, 2026.
- In the 2026-08-05 filing, market risk disclosures are stated to have no material changes during the six months ended June 30, 2026.
- In the 2026-08-05 filing, the legal proceedings section references Quarterly Reports on Form 10-Q for both the quarters ended March 31, 2026 and June 30, 2026.
- Removed:
- The 2026-05-01 filing stated no material changes to critical accounting policies and estimates during the three months ended March 31, 2026.
- The 2026-05-01 filing stated no material changes to market risk disclosures during the three months ended March 31, 2026.
- The 2026-05-01 filing referenced only the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 in the legal proceedings section.
- Reworded:
- The 2026-05-01 filing said 'Note 1, Significant accounting policies' while the 2026-08-05 filing says 'Note 1, Summary of significant accounting policies'.
- The 2026-05-01 filing said 'our Quarterly Report on Form 10-Q' (singular) while the 2026-08-05 filing says 'our Quarterly Reports on Form 10-Q' (plural).
- The 2026-05-01 filing concluded disclosure controls and procedures were effective as of March 31, 2026, while the 2026-08-05 filing concludes they were effective as of June 30, 2026.
- The 2026-05-01 filing stated no changes in internal control over financial reporting as of March 31, 2026, while the 2026-08-05 filing states the same as of June 30, 2026.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 6 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 6 sells ($4M) — 3 selling insiders
- Last 180 days · read to 2026-10-040 buys · 7 sells ($5M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-13. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AMGN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 30 matched disclosures for AMGN from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding AMGN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 88,375,012
- Reported value $32,002,359,771
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AMGN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AMGN had 14,063,517 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
AMGN had 2.60% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.94 days to cover at the same settlement.
- Reported short interest (shares) 14,063,517
- Short interest (% of shares outstanding) 2.60%
- Prior settlement (shares) 12,973,938
- Reported change 8.4%
- Days to cover (reported) 4.94
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AbbVie (ABBV)
- Bristol-Myers Squibb (BMY)
- Johnson & Johnson (JNJ)
- Merck & Co. (MRK)
- Pfizer (PFE)
- Gilead Sciences (GILD)
- Regeneron Pharmaceuticals (REGN)
- Eli Lilly (LLY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AMGN vs…
Amgen is found in…
AMGN ranks in…
Frequently asked questions
What does Amgen (AMGN) do?
Amgen is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics for serious illnesses. Its diverse portfolio includes treatments for inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology. The company is also active in the development of biosimilars and innovative small molecule and biologic therapies.
What sector is Amgen (AMGN) in?
Amgen (AMGN) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Does AMGN pay a dividend?
Yes — Amgen (AMGN) pays a dividend, with an indicated yield of about 2.61% and at least 15 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-09-03). Informational only — not financial advice.
Who are Amgen's (AMGN) competitors?
Notable peers of Amgen (AMGN) include AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Pfizer. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in AMGN?
Yes — we hold 30 matched STOCK Act disclosures for AMGN from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Amgen (AMGN) overbought or oversold right now?
Amgen (AMGN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AMGN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.